Document:

MICROLIN
BIO, INC. 

Scientific
Advisory Board Agreement

 

This
Scientific Advisory Board Agreement (the “Agreement”) is made and entered into as of December 19,
2013 (the “Effective Date”), by and between MicroLin Bio, Inc., a Delaware company, having its principal place
of business at 302A W. 12th Street, NY, NY 10014 (the “Company”), and Dr. Sakari Kauppinen, an individual
with an address at Norskekrogen 12, DK-2765 Smoerum, Denmark (the “Advisor”). The Company and the Advisor may
be referred to herein individually as “Party” or collectively, as “Parties.”

 

Recital

 

As part of its ongoing
program of research and development, the Company desires to retain distinguished scientists and other qualified individuals to
advise the Company with respect to its research and development and business strategy and to assist it in the research, development
and analysis of the Company’s technology and products. In furtherance thereof, the Company desires to retain Advisor as a
member of its Scientific Advisory Board as described below, and the Company and Advisor desire to enter into this Agreement to
effect such retention.

 

Agreement

 

In consideration of the mutual covenants
set forth below, the Parties hereby agree as follows:

 

1.          Scientific
Advisory Board and Consulting Services. Commencing as of the Effective Date, the Company
hereby retains the Advisor, and the Advisor hereby agrees to serve, as a member of the Company’s Scientific Advisory Board
(the “SAB”) and as a consultant to the Company. As member of the SAB, Advisor agrees to provide the services
as follows: (a) attending meetings of the Company’s SAB; (b) performing the duties of an SAB member at such meetings, as
established from time to time by the mutual agreement of the Company and the SAB members. As a consultant to the Company, the Advisor
will meet with Company employees, consultants and other SAB members, review goals of the Company and assist in developing strategies
for achieving such goals, and provide advice, support, theories, techniques and improvements in the Company’s scientific
research and product development activities; and (c) provide consulting services to the Company at its request, including a reasonable
amount of informal consultation over the telephone or otherwise as requested by the Company. These services to be provided by Advisor
hereunder are referred to collectively herein as the “Services.” Advisor shall annually provide ten (10) full
days of Services to the Company, pursuant to a mutually agreed schedule, as requested by the Company for each annual period and
agreed to by the Advisor. Advisor’s consultation with the Company will involve Services with respect to the field of microRNA
diagnostics and therapeutics (the “Field”) and requires the application of unique, special and extraordinary
skills and knowledge that Advisor possesses in the Field. Notwithstanding the foregoing appointments, it is agreed and understood
that the Company will not use the Advisors’s name or identify his institutional and non-institutional affiliations in any
advertising, promotional or sale literature, or other publicity without the prior written consent of the Advisor.

 

    	 

    	 

    

 

2.           Compensation.

 

As compensation for performing the Services,
the Company shall pay Advisor two hundred and fifty dollars ($250) hourly, payable quarterly (within ten (10) days of the end of
the applicable quarter) up to the maximum of eighty (80) hours total per year, unless otherwise agreed. The Company will also reimburse
Advisor for reasonable out-of-pocket expenses incurred by Advisor subject to the submission of reasonable documentation.

 

3.           Independent
Contractor. The Parties understand and agree that the Advisor is an independent contractor
and not an employee of the Company. Advisor has no authority to obligate the Company by contract or otherwise. Advisor will not
be eligible for any employee benefits, nor will the Company make deductions from Advisor’s fees for taxes (except as otherwise
required by applicable law or regulation). Any taxes imposed on Advisor due to activities performed hereunder will be the sole
responsibility of Advisor.

 

4.           Institutional
Affiliations. 

 

4.1.          The
Company acknowledges that the Advisor is a Professor at the Department of Haematology, Aalborg University Hospital (the “Institute”)
and is subject to the Institute’s policies, including policies concerning consulting, conflicts of interest and intellectual
property. The Company acknowledges that, to the extent that such policies conflict with the terms of this Agreement, Advisor’s
obligations under the Institute’s policies take priority and control over the obligations that Advisor has by reason of this
Agreement. The Company further acknowledges and agrees that nothing in this Agreement shall affect Advisor’s obligations
to, or research on behalf of, the Institute. Advisor agrees to use reasonable efforts to avoid or minimize any such conflict. Advisor
agrees that he will use best efforts to avoid using any facilities or resources of the Institute in performing the Services hereunder.

 

4.2.          Advisor
agrees to provide to the Company copies of Institute’s policies or guidelines relating to Advisor’s obligations to
the Institute and consulting services, if any, promptly upon request by the Company. If Advisor is required by the Institute, pursuant
to applicable guidelines or policies, to make any disclosure or take any action that conflicts with the Services being provided
by Advisor hereunder or is that contrary to the terms of this Agreement, Advisor will promptly notify the Company of such obligation,
specifying the nature of such disclosure or action and identifying the applicable guideline or policy under which disclosure or
action is required, prior to making such disclosure or taking such action.

 

4.3.         It
is agreed and understood that nothing in this AGREEMENT shall be construed to restrict or limit the duties Advisor is performing
or may perform in the course of, or incidental to, Advisor's employment at the Institute, including but not limited to research
sponsored by a third party commercial entity nor shall anything in the Agreement be construed to restrict or limit Advisor's right
to serve as an advisor to any hospital, or to any governmental or non-profit organization.

 

5.            Recognition
of Company’s Rights; Nondisclosure. Advisor recognizes that the Company is engaged
in a continuous program of research and development respecting its present and future business activities. Advisor agrees as follows:

 

    	2

    	 

    

 

5.1.          At
all times during the term of Advisor’s association with the Company and thereafter, Advisor will hold in strictest confidence
and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except
to the extent such disclosure, use or publication may be required in direct connection with Advisor’s performing requested
Services for the Company, is expressly authorized in writing by an officer of the Company, or is required by law.

 

5.2.          The
term “Proprietary Information” shall mean any and all trade secrets, confidential knowledge, know-how, data
or other proprietary information or materials of the Company. By way of illustration but not limitation, Proprietary Information
includes: (i) inventions, ideas, samples, prototypes, devices, hardware, software, electronic components and materials, and
procedures for producing any such items, as well as data, know-how, improvements, inventions, discoveries, developments, designs
and techniques; (ii) information regarding plans for research, development, new products, marketing and selling activities,
business models, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (iii) information
regarding the skills and compensation of employees or other consultants of the Company.

 

5.3.          In
addition, Advisor understands that the Company has received and in the future will receive from third parties confidential or proprietary
information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. During the term of Advisor’s association and thereafter,
Advisor will hold Third Party Information in the strictest confidence and will not disclose or use Third Party Information, except
in connection with Advisor’s performing requested Services for the Company, as expressly authorized in writing by an officer
of the Company, or is required by law.

 

5.4. It is agreed and understood that nothing
in this Agreement shall limit or be construed to limit the right of the Advisor to use or publish information which: (a) is or
becomes available to the public through no breach of the Agreement by Advisor, (b) was known to Advisor before the Services were
performed, (c) is acquired by Advisor from a third party that has the legal right to disclose the information to the Advisor or
(d) Advisor is required to disclose by law, government regulation, court order, or the Institute policies. In addition, information
generated by Advisor pursuant to the Agreement shall be proprietary to the Company only if: (a) such information is generated as
a direct result of the performance of the Services under the Agreement and (b) is not generated in the course of the Advisor’s
activities as an Institute employee.

 

6.           Intellectual
Property Rights.

 

6.1.          Advisor
agrees that any and all ideas, inventions, technologies, discoveries, improvements, know-how and techniques that the Advisor conceives,
reduces to practice or develops during the term of the Agreement, alone or in conjunction with others, but only in the course of
and directly related to the Advisor’s performing the Services for the Company under this Agreement (collectively, the “Inventions”)
shall be the sole and exclusive property of the Company. 

 

    	3

    	 

    

 

6.2.          Advisor
hereby assigns to the Company his entire right, title and interest in and to all Inventions. Advisor hereby designates the Company
as his agent for, and grants to the Company a power of attorney, which power of attorney shall be deemed coupled with an interest,
solely for the purpose of effecting the foregoing assignment from the Advisor to the Company. Advisor will perform other activities
necessary to effect the intent of this Section 6.2.

 

6.3.          Advisor
further agrees to reasonably cooperate and provide reasonable assistance to the Company to obtain and from time to time enforce
United States and foreign patents, copyrights, and other rights and protections claiming, covering or relating to the Inventions
in any and all countries, all at the Company’s expense.

 

6.4.          Advisor
agrees to submit to the Company any proposed publication that contains any discussion relating to the Company, Proprietary Information,
Inventions or work performed by Advisor for the Company hereunder. Advisor further agrees that no such publication shall be made
without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. 

 

6.5. Notwithstanding anything to the contrary
herein contained, the Company agrees and understands that the Advisor has a pre-existing obligation to assign to the Institute
all of his rights, title and interest in and to all intellectual property which arise or are derived from Advisor’s employment
at the Institute. The Company has no rights by reason of this Agreement in any publication, invention, discovery, improvement or
other intellectual property, whether or not publishable, patentable or copyrightable that is subject to Advisor’s obligations
to the Institute. Company also acknowledges and agrees that it will enjoy no priority or advantage as a result of the consultancy
created hereunder in gaining access, whether by license or otherwise, to any proprietary information or intellectual property of
the Institute. Other than the Inventions properly assigned to Company pursuant to this Article 6, Company shall have no rights,
title or interest in any other inventions, discoveries or developments owned by or assignable to the Institute.

 

7.           Noncompetition
and Nonsolicitation of Employees.

 

7.1.          During
the term of this Agreement, Advisor will not, without the prior consent of the Company’s Board of Directors, engage in any
commercial business activity that competes in any way with any business then being conducted by the Company in the Field, except
that Advisor may continue the affiliations set forth in Exhibit A. In addition, but without limiting the generality of the
foregoing, Advisor covenants and agrees during the term of this Agreement and for one year thereafter not to enter into any consulting
relationship in the Field with any third party commercial entity. The foregoing shall not prevent Advisor from engaging in his
work at the Institute or conducting any academic research, teaching or related non-commercial activity or any non-related commercial
activity.

 

7.2.          During
the term of this Agreement and for two (2) year after its termination, Advisor will not personally or through others recruit, solicit
or induce any employee of the Company to terminate his or her employment with the Company.

 

    	4

    	 

    

 

7.3.          If
any restriction set forth in Sections 7.1 and 7.2 is found by any court of competent jurisdiction to be unenforceable because it
extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted
to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

 

8.           No
Conflicting Obligation.

 

8.1.          Advisor
represents that Advisor’s performance of all of the terms of this Agreement and the performing of the Services for the Company
do not and will not breach or conflict with any agreement with a third party, except as contemplated by Section 4.1, including
an agreement to keep in confidence any proprietary information of another entity acquired by Advisor in confidence or in trust
prior to the date of this Agreement.

 

8.2.          Advisor
hereby agrees not to enter into any agreement that conflicts with this Agreement.

 

9.           No
Improper Use of Materials. Advisor agrees not to bring to the Company or to use in the performance
of Services for the Company any materials or documents of a present or former employer of Advisor, or any materials or documents
obtained by Advisor from a third party under a binder of confidentiality, unless such materials or documents are generally available
to the public or Advisor has authorization from such present or former employer or third party for the possession and unrestricted
use of such materials. Advisor understands that Advisor is not to breach any obligation of confidentiality that Advisor has to
present or former employers or clients, and agrees to fulfill all such obligations during the term of this Agreement.

 

10.         Term
and Termination.

 

10.1.          This
Agreement, and Advisor’s Services hereunder, shall commence on the Effective Date and shall continue for an initial term
of one (2) year after the Effective Date, unless earlier terminated as provided below. At the end of such initial term, the Agreement
will automatically be extended for an additional period or periods of one (1) year each, unless the Advisor or the Company shall
have given to the other written notice to the contrary at least thirty (30) days prior to the commencement of such additional period.

 

10.2.          Advisor
or the Company may terminate the Agreement at any time by giving no less than fifteen (15) days prior written notice to the other
Party.

 

10.3.          The
obligations set forth in Articles 2, 5, 6, 7 and 10 through 16 will survive any termination
or expiration of this Agreement. Upon termination of this Agreement, Advisor will promptly deliver to the Company all documents
and other materials of any nature pertaining to the Services, together with all documents and other items containing or pertaining
to any Proprietary Information.

 

11.         Assignment.
The rights and liabilities of the Parties hereto shall bind and inure to the benefit of their respective successors, heirs, executors
and administrators, as the case may be; provided that, as the Company has specifically contracted for Advisor’s Services,
Advisor may not assign or delegate Advisor’s obligations under this Agreement either in whole or in part without the prior
written consent of the Company. The Company may assign its rights and obligations hereunder to any person or entity that succeeds
to all or substantially all of the Company’s business. Any assignment not in accordance with this Section 11 shall be void.

 

    	5

    	 

    

 

12.         Legal
and Equitable Remedies. Because Advisor’s Services are personal and unique and because
Advisor may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right
to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice
to any other rights and remedies that the Company may have for a breach of this Agreement.

 

13.         Governing
Law; Severability. This Agreement shall be governed by and construed according to the laws
of the State of Delaware, without regards to conflicts of laws rules. If any provision of this Agreement is found by a court of
competent jurisdiction to be unenforceable, that provision shall be severed and the remainder of this Agreement shall continue
in full force and effect. The parties agree that the State and federal courts located within the First Department (for State courts)
and the Southern District of New York (for federal courts) shall be the venue for the initiation of any legal proceedings by a
party with respect to this Agreement.

 

14.         Complete
Understanding; Modification. This Agreement, and the Exhibit mentioned herein, constitute
the final, exclusive and complete understanding and agreement of the Parties hereto and supersedes all prior understandings and
agreements. Any waiver, modification or amendment of any provision of this Agreement shall be effective only if in writing and
signed by the Parties hereto.

 

15.         Notices.
Any notices required or permitted hereunder shall be given to the appropriate Party at the address listed on the first page of
the Agreement, or such other address as the Party shall specify in writing pursuant to this notice provision. Such notice shall
be deemed given upon personal delivery to the appropriate address or three days after the date of delivery if sent by certified
or registered mail, return receipt requested; or three days after the date of delivery if sent by an overnight delivery service
with verified delivery.

 

16.         Counterparts.
This Agreement may be executed in one or more counterparts each of which will be deemed an original, but all of which together
shall constitute one and the same instrument.

 

17.         Indemnification. The
Company shall indemnify, defend and hold harmless the Advisor from and against any and all third party claims against Advisor and
any costs, losses or expenses related thereto, including any reasonable legal fees and expenses, arising out of his services or
status as an Advisor hereunder, except to the extent such claims arise out of Advisor’s deliberate and material misconduct.
The Company shall reimburse the Advisor for any legal fees and all other expenses incurred by the Advisor in order to enforce the
provisions of this paragraph.

 

    	6

    	 

    

 

In
Witness Whereof, the Parties hereto have executed this Agreement as of the date first written above.

 

	Microlin Bio, Inc.	 	Dr. Sakari Kauppinen
	 	 	 
	/s/ Joe Hernandez	 	/s/ Sakari Kauppinen
	By: Joe Hernandez	 	By: Sakari Kauppinen
	Title: Chairman & CEO	 	Title: Professor

 

    	7

    	 

    

 

Exhibit
A

Affiliations

 

		1.	Professor, Department of Haematology, Aalborg University
Hospital

 

		2.	Senior Consultant, SK Pharma Consulting

 

    	8CONSULTING
AGREEMENT

 

 

THIS
CONSULTING AGREEMENT (the "Agreement") is made and entered into this day of May 21, 2015, (the "Effective Date")
by and between Microlin Bio, Inc., a Delaware corporation duly organized under law and having an usual place of business at 302A
W. 12 Street, Suite 114, New York, NY 10014 (hereinafter referred to as the "Company") and Bruce C. Galton (hereinafter
referred to as the "Consultant") residing at 8 Holden Lane Madison, NJ 07940

 

WHEREAS,
the Company wishes to engage the Consultant to provide the services described herein and Consultant agrees to provide the services
for the compensation and otherwise in accordance with the terms and conditions contained in this Agreement,

 

NOW
THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, accepted and agreed to, the Company and the Consultant, intending to be legally bound, agree to the terms
set forth below.

 

1.   TERM.
Commencing as of the Effective Date, and continuing for a period of one (1) year (the "Term"), unless earlier terminated
pursuant to Article 4 hereof, the Consultant agrees that he/she will serve as a consultant to the Company. This Agreement may
be renewed or extended for any period as may be agreed by the parties.

 

2.  DUTIES
AND SERVICES.

 

(a)                       
Consultant's duties and responsibilities shall be to provide business, operations, strategic, scientific and technical advice
and support to the company and its Chairman in the company's preclinical development efforts, including scientific planning, experimentation
design, data analysis and vendor selection and management. In addition, the consultant shall assist in document preparation, including
business plans, corporate presentation, S-1 document, financial model and other related material and work as requested by the
Company, the Executive management personnel or Board of Directors. The Consultant shall act as the Interim Chief Operating Officer
and report directly to the Chairman (collectively, the "Duties"or "Services").

 

(b)                      
The Consultant represents and warrants to the Company that he/she is under no contractual or other restrictions or obligations
which are inconsistent with the execution of this Agreement, or which will interfere with the performance of his/her Duties. Consultant
represents and warrants that the execution and performance of this Agreement will not violate any policies or procedures of any
other person or entity for which he/she performs Services concurrently with those performed herein.

    	 	 	 

     

    

 

(c)                      
In performing the Services, Consultant shall comply, to the best of his/her knowledge, with all business conduct, regulatory and
health and safety guidelines established by the Company for any governmental authority with respect to the Company's business.

 

3.  CONSULTING
FEE.

 

(a)                       
Subject to the provisions hereof, the Company shall pay Consultant a hourly consulting fee of $187.50 per hour, paid monthly (the
"Consulting Fee"). The Consultant agrees to devote a minimum of twenty (20) hours per month for services to the company.
The Consultant shall submit a brief summary report to the Company of her activities for the month just ended during the Term of
this Agreement. Additionally, the company will issue the option to purchase 20,000 of the company's outstanding shares at the
time of this agreement. These options shall vest over a four (4) year period as follows; twenty five percent (25%) of the shares
shall vest on the first anniversary of this agreement and the remaining shares shall vest on a monthly basis over the remaining
three-year period on a pro-rata basis. The Consultant acknowledges that this is the only form of compensation provide for his/her
services.

 

(b)                     
Consultant shall be entitled to prompt reimbursement for all pre-approved expenses incurred in the performance of his/her Duties,
upon submission and approval of written statements and receipts in accordance with the then regular procedures of the Company.

 

(c)                     
The Consultant agrees that all Services will be rendered by him/her as an independent contractor and that this Agreement does
not create an employer-employee relationship between the Consultant and the Company. The Consultant shall have no right to receive
any employee benefits including, but not limited to, health and accident insurance, life insurance, sick leave and/or vacation.
Consultant agrees to pay all taxes including, self-employment taxes due in respect of the Consulting Fee and to indemnify the
Company in the event the Company is required to pay any such taxes on behalf of the Consultant.

 

4.  EARLY
TERMINATION OF THE TERM.

 

(a)                     
If the Consultant voluntarily ceases performing his/her Duties, becomes physically or mentally unable to perform his/her Duties,
or is terminated for cause, then, in each instance, the Consulting Fee shall cease and terminate as of such date. Any termination
"For Cause" shall be made in good faith.

 

(b)                     
This Agreement may be terminated without cause by either party upon not less than fifteen (15) days prior written notice by either
party to the other.

    	 	2	 

     

    

(c)                     
Upon termination under Sections 4(a) or 4(b), neither party shall have any further obligations under this Agreement, except for
the obligations which by their terms survive this termination as noted in Section 16 hereof. Upon termination and, in any case,
upon the Company's request, the Consultant shall return immediately to the Company all Confidential Information, as hereinafter
defined, and copies thereof.

 

5. 
RESTRICTED ACTIVITIES. During the Term and for a period of five (5) year thereafter, Consultant will not, directly or indirectly:

 

(i) solicit or request any employee of or consultant to the Company to leave the employ of or cease consulting for the Company;

 

(ii) solicit or request any employee of or consultant to the Company to join the employ of, or begin consulting for, any individual
or entity that researches, develops, markets or sells products that compete with those of the Company. However, Company is aware
that Consultant is consulting with TK Biotech, Inc., a development stage oncology company whose sole technology is currently focused
on monoclonal antibodies to TK-1. Company agrees that Consultant's work with TK Biotech is not in conflict with that of the Company;

 

(iii) solicit or request any individual or entity that researches, develops, markets or sells products that compete with those of the
Company, to employ or retain as a consultant any employee or consultant of the Company; or

 

(iv)  induce or attempt to induce any supplier or vendor of the Company to terminate or breach any written or oral agreement or understanding
with the Company.

 

6.
PROPRIETARY  RIGHTS.

 

(a)                     
Definitions. For the purposes of this Article 6, the terms set forth below shall have the following meanings:

 

(i)  Concept
and Ideas. Those concepts and ideas disclosed by the Company to Consultant or which are first developed by Consultant during the
course of the performance of Services hereunder and which relate to the Company' present, past or prospective business activities,
services, and products, all of which shall remain the sole and exclusive property of the Company. The Consultant shall have no
publication rights and all of the same shall belong exclusively to the Company.

 

(ii)
Confidential Information. For the purposes of this Agreement, Confidential Information shall mean and collectively include: all
information relating to the business, plans and/or technology of the Company including, but not limited to technical information
including inventions, methods, plans, processes, specifications, characteristics, assays, raw data, scientific preclinical or
clinical data, records, databases, formulations, clinical protocols, equipment design, know-how, experience, and trade secrets;
developmental, marketing, sales, customer, supplier, consulting relationship information, operating, performance, and cost information;
computer programming techniques whether in tangible or intangible form, and all record bearing media containing or disclosing
the foregoing information and techniques including, written business plans, patents and patent applications, grant applications,
notes, and memoranda, whether in writing or presented, stored or maintained in or by electronic, magnetic, or other means.

 

    	 	3	 

     

    

 

Notwithstanding
the foregoing, the term "Confidential Information" shall not include any information which: (a) can be demonstrated
to have been in the public domain or was publicly known or available prior to the date of the disclosure to Consultant; (b) can
be demonstrated in writing to have been rightfully in the possession of Consultant prior to the disclosure of such information
to Consultant by the Company; (c) becomes part of the public domain or publicly known or available by publication or otherwise,
not due to any unauthorized act or omission on the part of Consultant; or (d) is supplied to Consultant by a third party without
binder of secrecy, so long as that such third party has no obligation to the Company or any of its affiliated companies to maintain
such information in confidence.

 

(b)                       
Non-Disclosure  to  Third  Parties.  Except  as  required  by  Consultant's Duties, Consultant shall not, at any time now or in
the future, directly or indirectly, use, publish, disseminate or otherwise  disclose any Confidential Information, Concepts, or
Ideas to any third party without the prior written consent of the Company which consent may be denied in each instance and all
of the same, together with publication rights, shall belong exclusively to the Company.

 

(c)                      
Documents, etc. All documents, diskettes, tapes, procedural manuals, guides, specifications, plans, drawings, designs and similar
materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and
data relating to the pricing of the Company' products and services, records, notebooks and all other materials containing Confidential
Information or information about Concepts or Ideas (including all copies and reproductions thereof), that come into Consultant's
possession or control by reason of Consultant's performance of the relationship, whether prepared by Consultant or others: (a)
are the property of the Company, (b) will not be used by Consultant in any way other than in connection with the performance of
his/her Duties, (c) will not be provided or shown to any third party by Consultant, (d) will not be removed from the Company's
or Consultant's premises (except as Consultant's Duties require), and (e) at the termination (for whatever reason), of Consultant's
relationship with the Company, will be left with, or forthwith returned by Consultant to the Company.

    	 	4	 

     

    

 

(d)                     
Patents. etc. The Consultant agrees that the Company is and shall remain the exclusive owner of the Confidential Information and
Concepts and Ideas. Any interest in patents, patent applications, inventions, technological innovations, trade names, trademarks,
service marks, copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, know-how, data and analysis,
whether registrable or not ("Developments"), which Consultant, as a result of rendering Services to the Company under
this Agreement, may conceive or develop, shall: (i) forthwith be brought to the attention of the Company by Consultant and (ii)
belong exclusively to the Company. No license or conveyance of any such rights to the Consultant is granted or implied under this
Agreement

 

(e)                       
Assignment. The Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby agrees to assign
to the Company, without further compensation, all of his/her right, title and interest in and to all Concepts, Ideas, and Developments.
The Consultant will execute all documents and perform all lawful acts which the Company considers necessary or advisable to secure
its rights hereunder and to carry out the intent of this Agreement.

 

7.     
 EQUITABLE RELIEF. Consultant agrees that any breach of Articles 5 and 6 above by him/her would cause irreparable damage to
the Company and that, in the event of such breach, the Company shall have, in addition to any and all remedies of law, the right
to an injunction, specific performance or other equitable relief to prevent the violation or threatened violation of Consultant's
obligations hereunder.

 

8.     
WAIVER. Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver
of any subsequent breach of the same or any other provision hereof. All waivers by the Company shall be in writing.

 

9.     
SEVERABILITY; REFORMATION. In case any one or more of the provisions or parts of a provision contained in this Agreement shall,
for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provision or part of a provision of this Agreement; and this Agreement shall, to the fullest extent
lawful, be reformed and construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never
been contained herein, and such provision or part reformed so that it would be valid, legal and enforceable to the maximum extent
possible. Without limiting the foregoing, if any provision (or part of provision) contained in this Agreement shall for any reason
be held to be excessively broad as to duration, activity or subject, it shall be construed by limiting and reducing it, so as
to be enforceable to the fullest extent compatible with then existing applicable law.

 

10.    
ASSIGNMENT. The Company shall have the right to assign its rights and obligations under this Agreement to a party which assumes
the Company' obligations hereunder. Consultant shall not have the right to assign his/her rights or obligations under this Agreement
without the prior written consent of the Company. This Agreement shall be binding upon and inure to the benefit of the Consultant's
heirs and legal representatives in the event of his/her death or disability.

 

    	 	5	 

     

    

 

11.  HEADINGS.
Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

12.  AMENDMENTS.
 This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed by all parties hereto.

 

13.  NOTICES.
Any notices or other communications required hereunder shall be in writing and shall be deemed given when delivered in person
or when mailed, by certified or registered first class mail, postage prepaid, return receipt requested, addressed to the parties
at their addresses specified in the preamble to this Agreement or to such other addresses of which a party shall have notified
the others in accordance with the provisions of this Section 13.

 

14. COUNTERPART
S. This Agreement may be executed in two or more counterparts, each of which shall constitute an original and all of which
shall be deemed a single agreement.

 

15.  GOVERNING
LAW. This Agreement shall be construed in accordance with and governed for all purposes by the laws of the state of New York
applicable to contracts executed and wholly performed within such jurisdiction. Any dispute arising hereunder shall be referred
to and heard in only a court located in New York.

 

16. 
SURVIVAL. The provisions of Sections 5 to 9 and 15 to 16 of this Agreement shall survive the expiration of the Term or the
termination of this Agreement. This Agreement supersedes all prior agreements, written or oral, between the Company and the Consultant
relating to the subject matter of this Agreement.

 

EXECUTED,
under seal, effective as of the Effective Date.

 

	MICROLIN
                                         BIO, INC.

         

         

         

        By:
        /s/ Joe Hernandez

        Joe
        Hernandez

        Executive
        Chairman

        Hereunto
        Duly Authorized
	CONSULTANT

         

         

         

        /s/
        Bruce C. Galton

        Bruce
        C. Galton

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]